Sai Life Sciences Q2 FY27: revenue up 22.5% to ₹659 Cr, net profit up 17.3% to ₹98 Cr
Results · Finvezto · 6 Nov 2026 · Sai Life Sciences (SAILIFE)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 659 | +18.8% | +22.5% |
| Operating profit | 186 | +25.9% | +27.8% |
| Net profit | 98 | +34.1% | +17.3% |
| Operating margin | 28.3% | +1.6 pp | +1.2 pp |
| Net margin | 14.9% | +1.7 pp | -0.7 pp |
Key points
- Sai Life Sciences Limited reported consolidated revenue from operations of Rs 659 crore for Q2 FY27, up 23% from Rs 537 crore in Q2 FY26, with EBITDA of Rs 187 crore and PAT of Rs 98 crore. NSE filing
- Capital expenditure reached Rs 621 crore in H1 FY27 to support capacity expansion across its CRO and CDMO businesses. NSE filing
- Revenue was ₹659 Cr, up 22.5% on a year earlier and up 18.8% on the quarter before. Finvezto data
Other figures
- Capex: ₹621 Cr
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 33.8%, 29.3%, 26.7%, 28.3%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 100, 104, 73, 98.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.